Natalia Lazorko
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Natalia Lazorko has a total of 81 co-authors. Here are the top co-authors by number of shared publications:
- Nadezhda Shnalieva
VA Almazov National Medical Research Center, 2 Akkuratova ul., Saint Petersburg, Russian Federation, 197341
6 shared publications - Olga Kulemina
VA Almazov National Medical Research Center, 2 Akkuratova ul., Saint Petersburg, Russian Federation, 197341
5 shared publications - E. G. Lomaia
VA Almazov National Medical Research Center, 2 Akkuratova ul., Saint Petersburg, Russian Federation, 197341
4 shared publications Elza Lomaia
Almazov National Medical Research Centre, St. Petersburg, Russian Federation
4 shared publications- Nadiya Siordiya
VA Almazov National Medical Research Center, 2 Akkuratova ul., Saint Petersburg, Russian Federation, 197341
4 shared publications Tamara Chitanava
Almazov National Medical Research Centre, Saint-Petersburg, Russian Federation
4 shared publications
Latest Publications
- Open Access
- 1 October 2026
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 19 (4) , 419-433
Ponatinib Efficacy in Chronic Phase Chronic Myeloid Leukemia: Data from Three Centers in the Russian Federation
AIM. To assess the efficacy and tolerability of ponatinib in patients with the 1st chronic phase (CP) of chronic myeloid leukemia (CML) and with either prior tyrosine kinase inhibitor (ITK) resistance or the T315I mutation in the BCR::ABL1 gene. MATERIALS & METHODS. The study is based on the retrospective analysis of 99 CP CML patients treated with ponatinib in ≥ 2 therapy lines (83.8 % in the third and subsequent lines) as part of the clinical studies OPTIC, OPTIC-2L, and expanded access program in three medical institutions of the Russian Federation. The T315I mutation was identified in 31/96 patients (32.3 %). Most patients (86/99; 58.6 %) did not show complete hematologic response upon the start of ponatinib therapy, and 39/99 patients (39.4 %) did not achieve any cytogenetic response (CyR) on prior ITK therapy lines. RESULTS. On ponatinib therapy, the percentage of patients with complete CyR and molecular response 2 (CCyR/MR2) as well as major (MMR) and deep molecular response (DMR) was 55.4 %, 43.4 %, and 33.7 %, respectively. The median ponatinib therapy duration was 27.6 months (range 0.5–88.5 months). The probability of achieving CCyR/MR2 within 1 and 2 years of therapy was 45.9 % and 57.0 %, respectively. The median time before achieving CCyR/MR2 was 2.8 months (range 2.7–43.1 months), 38/51 patients (74.5 %) maintained CCyR/MR2 for 24 months. The number of patients with the T315I mutation and CCyR/MR2 was 12/31 (38.7 %), and the median time before achieving MR2 appeared to be comparable with that in the total cohort, i.e., 2.8 months (range 2.7–8.3 months). About half of patients achieved MMR and DMR by the 5th year of ponatinib therapy (57.7 % and 49.4 %, respectively). The median time before achieving MMR and DMR was 9.6 months (range 2.7–70.9 months) and 22.3 months (range 2.7–82.7 months), respectively. The multivariate regression analysis revealed favorable predictors of MR2 and MMR: BCR::ABL1 expression level ≤ 10 %, absence of mutations, and age ≤ 42 years at the start of ponatinib therapy. Rates of the 5-year OS, PFS, and EFS were 85.2 %, 86.6 %, and 34.3 %, respectively. CONCLUSION. Ponatinib demonstrated high efficacy both in patients with the T315I mutation and in heavily pre-treated patients. This study showed that baseline high level of BCR::ABL1 gene transcript or/and the absence of any CyR dramatically worsen long-term therapy outcomes. Another unfavorable prognostic factor is a failure to achieve CCyR/MR2 within the 1st year of ponatinib therapy, which calls for finding alternative treatment.
- 1 October 2026
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 19 (4) , 419-433
Open AccessPonatinib Efficacy in Chronic Phase Chronic Myeloid Leukemia: Data from Three Centers in the Russian Federation
AIM. To assess the efficacy and tolerability of ponatinib in patients with the 1st chronic phase (CP) of chronic myeloid leukemia (CML) and with either prior tyrosine kinase inhibitor (ITK) resistance or the T315I mutation in the BCR::ABL1 gene. MATERIALS & METHODS. The study is based on the retrospective analysis of 99 CP CML patients treated with ponatinib in ≥ 2 therapy lines (83.8 % in the third and subsequent lines) as part of the clinical studies OPTIC, OPTIC-2L, and expanded access program in three medical institutions of the Russian Federation. The T315I mutation was identified in 31/96 patients (32.3 %). Most patients (86/99; 58.6 %) did not show complete hematologic response upon the start of ponatinib therapy, and 39/99 patients (39.4 %) did not achieve any cytogenetic response (CyR) on prior ITK therapy lines. RESULTS. On ponatinib therapy, the percentage of patients with complete CyR and molecular response 2 (CCyR/MR2) as well as major (MMR) and deep molecular response (DMR) was 55.4 %, 43.4 %, and 33.7 %, respectively. The median ponatinib therapy duration was 27.6 months (range 0.5–88.5 months). The probability of achieving CCyR/MR2 within 1 and 2 years of therapy was 45.9 % and 57.0 %, respectively. The median time before achieving CCyR/MR2 was 2.8 months (range 2.7–43.1 months), 38/51 patients (74.5 %) maintained CCyR/MR2 for 24 months. The number of patients with the T315I mutation and CCyR/MR2 was 12/31 (38.7 %), and the median time before achieving MR2 appeared to be comparable with that in the total cohort, i.e., 2.8 months (range 2.7–8.3 months). About half of patients achieved MMR and DMR by the 5th year of ponatinib therapy (57.7 % and 49.4 %, respectively). The median time before achieving MMR and DMR was 9.6 months (range 2.7–70.9 months) and 22.3 months (range 2.7–82.7 months), respectively. The multivariate regression analysis revealed favorable predictors of MR2 and MMR: BCR::ABL1 expression level ≤ 10 %, absence of mutations, and age ≤ 42 years at the start of ponatinib therapy. Rates of the 5-year OS, PFS, and EFS were 85.2 %, 86.6 %, and 34.3 %, respectively. CONCLUSION. Ponatinib demonstrated high efficacy both in patients with the T315I mutation and in heavily pre-treated patients. This study showed that baseline high level of BCR::ABL1 gene transcript or/and the absence of any CyR dramatically worsen long-term therapy outcomes. Another unfavorable prognostic factor is a failure to achieve CCyR/MR2 within the 1st year of ponatinib therapy, which calls for finding alternative treatment.
- Open Access
- 1 April 2026
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 19 (2)
NK-Cell Receptor Repertoire in Chronic Myeloid Leukemia
BACKGROUND. Escape of leukemia cells from immune surveillance appears to be one of the most relevant areas in the study of resistance mechanisms in chronic myeloid leukemia (CML). AIM. To study the characteristics of the NK-cell immune response in patients with chronic phase (CP) CML on third-line therapy with tyrosine kinase inhibitors (TKIs) of the second generation. MATERIALS & METHODS. The study enrolled 40 CML CP patients receiving third-line therapy at the VA Almazov National Medical Research Center. The control group consisted of 20 healthy subjects (HS). The quantitative characteristics of NK- and TNK-cells as well as the expression of activating and inhibitory receptors on NK-cells were assessed using flow cytometry. KIR (Killer cell Immunoglobulin-like Receptors) haplotypes were analyzed by PCR and electrophoresis of PCR amplification products. RESULTS. Irrespective of treatment response, CML patients showed no significant differences regarding either the quantitative characteristics of NK- and TNK-cells or activating and inhibitory receptors on NK-cells. However, in the quantitative characteristics of inhibitory KIR alleles as well as in the expression of two activating KIR alleles (KIR2DS4 and KIR3DS1), significant differences were identified in HS vs. CML patients (p < 0.05). At the same time, the expression rate was similar in the groups with optimal response and therapy resistance (p = 0.25). There were also no significant differences in the rate of KIR haplotypes in HS and two groups of patients. In most CML patients as well as in HS, Bx haplotype of KIR was identified. The percentage of deaths was higher in the group with A haplotype (4/9; 45 %) vs. Bx haplotype (4/31; 13 %) (p = 0.008). The median progression-free survival (PFS) in the A haplotype subgroup was 76 (range 24–162) months vs. 69 (range 3–179) months in the Bx haplotype subgroup; the median overall survival (OS) was 69 (18–179) months vs. 76 (24–159) months, respectively. CONCLUSION. No significant differences were revealed in the expression of activating and inhibitory receptors on NK-cells in both groups of patients with response to TKI third-line therapy and therapy resistance compared to HS. This study demonstrated that NK-cell immune response had no effect on complete cytogenetic response. The results of the study suggest that the assessment of NK-cell immune response and KIR haplotypes cannot be regarded as a valuable tool for predicting the treatment efficacy in CML CP patients. However, due to heterogeneity of the groups under this study, further research is necessary to understand the prognostic value of KIR haplotypes in achieving response to therapy as well as their effect on OS and PFS.
- 1 April 2026
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 19 (2)
Open AccessNK-Cell Receptor Repertoire in Chronic Myeloid Leukemia
BACKGROUND. Escape of leukemia cells from immune surveillance appears to be one of the most relevant areas in the study of resistance mechanisms in chronic myeloid leukemia (CML). AIM. To study the characteristics of the NK-cell immune response in patients with chronic phase (CP) CML on third-line therapy with tyrosine kinase inhibitors (TKIs) of the second generation. MATERIALS & METHODS. The study enrolled 40 CML CP patients receiving third-line therapy at the VA Almazov National Medical Research Center. The control group consisted of 20 healthy subjects (HS). The quantitative characteristics of NK- and TNK-cells as well as the expression of activating and inhibitory receptors on NK-cells were assessed using flow cytometry. KIR (Killer cell Immunoglobulin-like Receptors) haplotypes were analyzed by PCR and electrophoresis of PCR amplification products. RESULTS. Irrespective of treatment response, CML patients showed no significant differences regarding either the quantitative characteristics of NK- and TNK-cells or activating and inhibitory receptors on NK-cells. However, in the quantitative characteristics of inhibitory KIR alleles as well as in the expression of two activating KIR alleles (KIR2DS4 and KIR3DS1), significant differences were identified in HS vs. CML patients (p < 0.05). At the same time, the expression rate was similar in the groups with optimal response and therapy resistance (p = 0.25). There were also no significant differences in the rate of KIR haplotypes in HS and two groups of patients. In most CML patients as well as in HS, Bx haplotype of KIR was identified. The percentage of deaths was higher in the group with A haplotype (4/9; 45 %) vs. Bx haplotype (4/31; 13 %) (p = 0.008). The median progression-free survival (PFS) in the A haplotype subgroup was 76 (range 24–162) months vs. 69 (range 3–179) months in the Bx haplotype subgroup; the median overall survival (OS) was 69 (18–179) months vs. 76 (24–159) months, respectively. CONCLUSION. No significant differences were revealed in the expression of activating and inhibitory receptors on NK-cells in both groups of patients with response to TKI third-line therapy and therapy resistance compared to HS. This study demonstrated that NK-cell immune response had no effect on complete cytogenetic response. The results of the study suggest that the assessment of NK-cell immune response and KIR haplotypes cannot be regarded as a valuable tool for predicting the treatment efficacy in CML CP patients. However, due to heterogeneity of the groups under this study, further research is necessary to understand the prognostic value of KIR haplotypes in achieving response to therapy as well as their effect on OS and PFS.
- Open Access
- 1 January 2026
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 19 (1) , 14-26
Quality of Life and Symptom Profile in Polycythemia Vera Patients on Ruxolitinib Therapy in a Real-World Setting: Results of a Multi-Center Prospective Observational Study
AIM. To assess the changes in quality of life and symptom profile in polycythemia vera (PV) patients during ruxolitinib treatment as well as to study the efficacy and safety of this drug in a real-world setting. MATERIALS & METHODS. This multi-center prospective observational study enrolled 50 PV patients from 9 medical centers of the Russian Federation (median age 58 years, male/female ratio 1:1). All patients had indications for ruxolitinib therapy. The median disease duration was 48.3 months. Splenomegaly was observed in 86 % of cases; stratification of patients yielded an intermediate/high-risk group with 76 % and low-risk group with 24 % of them. Patients completed SF-36 and MPN10 questionnaires prior to treatment and then 1, 3, 6, 9, and 12 months after therapy onset along with a patient satisfaction checklist. Clinic response was assessed in accordance with the National Clinical Guidelines. The total MPN10 score decrease by ≥ 50 % during the treatment was regarded as a symptom-related response. The statistical analysis of the parameters changing over time was performed using generalized estimating equations (GEE). RESULTS. Ruxolitinib therapy for 12 months resulted in pronounced positive changes in quality of life and symptom reduction in patients with both intermediate/high and low risk of thrombotic complications (p < 0.001). Therapy response with total MPN10 score decrease ≥ 50 % was observed in 59 % of patients after 1 month and in 70 % of patients in subsequent treatment periods. Nine months after therapy onset, a complete clinical and hematologic response was achieved in 57.8 % and a partial one in 37.8 % of patients; after 12 months it was reported in 59.2 % and 36.7 % of patients, respectively. Hematocrit improvement was achieved in more than 85 % of cases in different treatment periods. Adverse events (AEs), commonly grade 1/2, were identified in 11 (22 %) patients, and serious AEs (ischemic stroke and second tumor) were detected in 2 patients. During the follow-up period, the vast majority of PV patients reported improved well-being and satisfaction with ruxolitinib treatment outcomes. CONCLUSION. In a real-world setting, ruxolitinib therapy showed good clinical efficacy, favorable safety profile as well as pronounced positive changes in quality of life and disease symptoms throughout 12 months after therapy onset.
- 1 January 2026
- Published by Practical Medicine Publishing House in Clinical oncohematology
- Vol. 19 (1) , 14-26
Open AccessQuality of Life and Symptom Profile in Polycythemia Vera Patients on Ruxolitinib Therapy in a Real-World Setting: Results of a Multi-Center Prospective Observational Study
AIM. To assess the changes in quality of life and symptom profile in polycythemia vera (PV) patients during ruxolitinib treatment as well as to study the efficacy and safety of this drug in a real-world setting. MATERIALS & METHODS. This multi-center prospective observational study enrolled 50 PV patients from 9 medical centers of the Russian Federation (median age 58 years, male/female ratio 1:1). All patients had indications for ruxolitinib therapy. The median disease duration was 48.3 months. Splenomegaly was observed in 86 % of cases; stratification of patients yielded an intermediate/high-risk group with 76 % and low-risk group with 24 % of them. Patients completed SF-36 and MPN10 questionnaires prior to treatment and then 1, 3, 6, 9, and 12 months after therapy onset along with a patient satisfaction checklist. Clinic response was assessed in accordance with the National Clinical Guidelines. The total MPN10 score decrease by ≥ 50 % during the treatment was regarded as a symptom-related response. The statistical analysis of the parameters changing over time was performed using generalized estimating equations (GEE). RESULTS. Ruxolitinib therapy for 12 months resulted in pronounced positive changes in quality of life and symptom reduction in patients with both intermediate/high and low risk of thrombotic complications (p < 0.001). Therapy response with total MPN10 score decrease ≥ 50 % was observed in 59 % of patients after 1 month and in 70 % of patients in subsequent treatment periods. Nine months after therapy onset, a complete clinical and hematologic response was achieved in 57.8 % and a partial one in 37.8 % of patients; after 12 months it was reported in 59.2 % and 36.7 % of patients, respectively. Hematocrit improvement was achieved in more than 85 % of cases in different treatment periods. Adverse events (AEs), commonly grade 1/2, were identified in 11 (22 %) patients, and serious AEs (ischemic stroke and second tumor) were detected in 2 patients. During the follow-up period, the vast majority of PV patients reported improved well-being and satisfaction with ruxolitinib treatment outcomes. CONCLUSION. In a real-world setting, ruxolitinib therapy showed good clinical efficacy, favorable safety profile as well as pronounced positive changes in quality of life and disease symptoms throughout 12 months after therapy onset.
- Open Access
- 30 July 2025
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 10,p. 94-102
Efficacy and safety of the second-generation tyrosine kinase inhibitor bosutinib in the treatment of chronic myeloid leukemia in the chronic phase
Introduction. ABL tyrosine kinase inhibitors (TKIs) have significantly improved the treatment outcomes for patients with chronic myeloid leukemia (CML). Bosutinib is a second-generation TKI that has demonstrated high efficacy and safety in clinical trials in firstand subsequent-line therapy of CML.Aim. To evaluate the long-term efficacy and safety of bosutinib in real-world clinical practice.Materials and methods. In our retrospective study all patients in the first chronic phase of CML who had ever received bosutinib therapy as their first, second, or third TKI were included. Only 4 patients (2 men) aged from 30 to 41 years received bosutinib as first TKI. Bosutinib was administered as second or third TKI to 19 patients (12 men) with a median age of 50 (31–71) and 17 patients (8 men) with a median age of 49.8 (21–70), respectively. Most patients had a long history of CML and most of them were resistant to previous TKIs.Results. All four patients who received bosutinib in the first-line achieved a complete hematological response (CHR), and three (75%) of them achieved a complete cytogenetic response (CCR) and a major molecular response (MMR). All 3 patients with MMR continued therapy for more than 16 years without significant adverse events. Among patients with bosutinib treatment after failure of imatinib or 2 TKIs, the CHR was achieved in most cases, and major cytogenetic response (MCR) was achieved in 7/19 (36.8%) and 6/17 (35.3%) cases. During the observation period, the median overall survival was not reached. There were few cases of bosutinib discontinuation due to drug intolerance. Long-term use of the drug did not lead to serious delayed side effects, including cardiovascular complications, associated with bosutinib therapy.Conclusions. Thus, in our group of patients with long-term observation, bosutinib showed not only a high frequency of achieving an optimal response in all lines of therapy in CP CML, but also the absence of severe remote complications, both hematological and non-hematological.
- 30 July 2025
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 10,p. 94-102
Open AccessEfficacy and safety of the second-generation tyrosine kinase inhibitor bosutinib in the treatment of chronic myeloid leukemia in the chronic phase
Introduction. ABL tyrosine kinase inhibitors (TKIs) have significantly improved the treatment outcomes for patients with chronic myeloid leukemia (CML). Bosutinib is a second-generation TKI that has demonstrated high efficacy and safety in clinical trials in firstand subsequent-line therapy of CML.Aim. To evaluate the long-term efficacy and safety of bosutinib in real-world clinical practice.Materials and methods. In our retrospective study all patients in the first chronic phase of CML who had ever received bosutinib therapy as their first, second, or third TKI were included. Only 4 patients (2 men) aged from 30 to 41 years received bosutinib as first TKI. Bosutinib was administered as second or third TKI to 19 patients (12 men) with a median age of 50 (31–71) and 17 patients (8 men) with a median age of 49.8 (21–70), respectively. Most patients had a long history of CML and most of them were resistant to previous TKIs.Results. All four patients who received bosutinib in the first-line achieved a complete hematological response (CHR), and three (75%) of them achieved a complete cytogenetic response (CCR) and a major molecular response (MMR). All 3 patients with MMR continued therapy for more than 16 years without significant adverse events. Among patients with bosutinib treatment after failure of imatinib or 2 TKIs, the CHR was achieved in most cases, and major cytogenetic response (MCR) was achieved in 7/19 (36.8%) and 6/17 (35.3%) cases. During the observation period, the median overall survival was not reached. There were few cases of bosutinib discontinuation due to drug intolerance. Long-term use of the drug did not lead to serious delayed side effects, including cardiovascular complications, associated with bosutinib therapy.Conclusions. Thus, in our group of patients with long-term observation, bosutinib showed not only a high frequency of achieving an optimal response in all lines of therapy in CP CML, but also the absence of severe remote complications, both hematological and non-hematological.
- Open Access
- 2 November 2023
- Published by American Society of Hematology in Blood
- Vol. 142 (Supplement) , 1803
The Updated Results of Asciminib Managed-Access Program (MAP) in Patients with Chronic Myeloid Leukemia in Russia
Background: Therapy choice in chronic myeloid leukemia (CML) patients (pts) with ≥2 lines of tyrosine kinase inhibitors (TKIs) failure or in pts with T315I mutationis a relevant problem. Efficacy and good tolerability of a first-in-class BCR::ABL1 allosteric inhibitor Asciminib (ASC) in chronic phase (CP) CML pts were confirmed in clinical trials. The out-study world data of ASC use in Managed Access Program (MAP) is of particular interest. Aim: to report the updated results of the ASC use within MAP in 3 clinical centers of Russia. Methods : Adult (≥18 years) CML pts with the lack of efficacy or intolerance to ≥2 lines of TKIs or T315I-positive pts after ≥1 prior TKI were included into a MAP. Inclusion criteria for our analysis were: CML-CP, ASC therapy for >3 months (mo). Two dosing regimen were used: 40 mg BID in BCR::ABL1 T315I-negative pts (40BID group) and 200 mg BID in BCR::ABL1 T315I-positive pts (200BID group). Complete cytogenetic response (CCyR, equivalent of MR2 or BCR::ABL1≤1%), major molecular response (MMR) and deep molecular response (MR4) achievement was assessed by cumulative incidence function (CIF) with Gray's test for comparison. Survival analysis was performed by Kaplan-Meier method according to “intention-to-treat” principle. Results: A total 82 pts received ASC in the MAP, 68 of them met the criteria for analysis (baseline characteristics are in table 1), while 14 were excluded. The median follow-up was 26 mo (range 4-49). The 2-year overall survival was 93% and 83%, the progression free survival was 90% and 70% in 40BID and 200BID groups, respectively. In 40BID group 17/43 pts discontinued ASC: 2 progressed to AP/BP, 2 - for bone marrow transplantation (BMT), 13 - failure (3 pts died due to CML after ASC discontinuation). In 200BID group 12/25 pts discontinued ASC: 2 developed AP, 3 -BMT, 7 - failure (one pt died). CIF of CCyR/MMR/MR4 by 24 mo was 58%/68%/19% in 40BID group and 65%/56%/32% in 200BID group. The achieved CCyR was preserved in 93% (14/15) and 77% (10/13) pts in 40BID and 200BID group, respectively. CIF of MMR in ponatinib-naïve pts was higher in both groups than in ponatinib-pretreated pts (picture). Dose escalation to 80-100 mg BID in 8/43 pts of 40BID group (due to lack of efficacy) resulted in achieving MMR for 2/8 pts with no MMR before escalation. Dose reduction in two groups was done both for adverse events (AEs) grade 3-4 (n=8) and stable MR4,5. In 4 pts (200BID) with no AEs and having a stable MR4,5 for >1 year, no MR4,5 loss was observed after ASC dose reduction to 100 mg BID. Subclone with emerging a new mutation was detected in 3 pts of 40BID group (A337T, G250A, T315I) while no new mutations were found in 200 mg BID group. AEs associated with ASC have been identified in 27/43 pts and 13/25 pts in 40BID and 200BID group, respectively, with no significant difference in AE spectrum and frequency. Most common (≥5%) AEs in two groups were: thrombocytopenia (29%), neutropenia (18%), cholesterol high (13%), anemia (6%), skin rash (5%). AEs grade 3-4 were detected in 13 (30%) and 4 (16%) pts in 40BID and 200BID group, respectively, and mostly presented by hematologic/cytopenic AEs (24%). No pt discontinued ASC due to toxicity, no arterial occlusive AEs were observed. Conclusion: ASC shows effectiveness and good safety profile in pts after prior failure to TKIs and those with T315I mutation. The CIF of any response was higher in ponatinib-naive pts at any dose. Different mutational subclones evolution was observed, including emergence of myristoyl-site mutation in 1 pt. ASC half dose reduction was safe in pts with previous MR4,5 stable response.
- 2 November 2023
- Published by American Society of Hematology in Blood
- Vol. 142 (Supplement) , 1803
Open AccessThe Updated Results of Asciminib Managed-Access Program (MAP) in Patients with Chronic Myeloid Leukemia in Russia
Background: Therapy choice in chronic myeloid leukemia (CML) patients (pts) with ≥2 lines of tyrosine kinase inhibitors (TKIs) failure or in pts with T315I mutationis a relevant problem. Efficacy and good tolerability of a first-in-class BCR::ABL1 allosteric inhibitor Asciminib (ASC) in chronic phase (CP) CML pts were confirmed in clinical trials. The out-study world data of ASC use in Managed Access Program (MAP) is of particular interest. Aim: to report the updated results of the ASC use within MAP in 3 clinical centers of Russia. Methods : Adult (≥18 years) CML pts with the lack of efficacy or intolerance to ≥2 lines of TKIs or T315I-positive pts after ≥1 prior TKI were included into a MAP. Inclusion criteria for our analysis were: CML-CP, ASC therapy for >3 months (mo). Two dosing regimen were used: 40 mg BID in BCR::ABL1 T315I-negative pts (40BID group) and 200 mg BID in BCR::ABL1 T315I-positive pts (200BID group). Complete cytogenetic response (CCyR, equivalent of MR2 or BCR::ABL1≤1%), major molecular response (MMR) and deep molecular response (MR4) achievement was assessed by cumulative incidence function (CIF) with Gray's test for comparison. Survival analysis was performed by Kaplan-Meier method according to “intention-to-treat” principle. Results: A total 82 pts received ASC in the MAP, 68 of them met the criteria for analysis (baseline characteristics are in table 1), while 14 were excluded. The median follow-up was 26 mo (range 4-49). The 2-year overall survival was 93% and 83%, the progression free survival was 90% and 70% in 40BID and 200BID groups, respectively. In 40BID group 17/43 pts discontinued ASC: 2 progressed to AP/BP, 2 - for bone marrow transplantation (BMT), 13 - failure (3 pts died due to CML after ASC discontinuation). In 200BID group 12/25 pts discontinued ASC: 2 developed AP, 3 -BMT, 7 - failure (one pt died). CIF of CCyR/MMR/MR4 by 24 mo was 58%/68%/19% in 40BID group and 65%/56%/32% in 200BID group. The achieved CCyR was preserved in 93% (14/15) and 77% (10/13) pts in 40BID and 200BID group, respectively. CIF of MMR in ponatinib-naïve pts was higher in both groups than in ponatinib-pretreated pts (picture). Dose escalation to 80-100 mg BID in 8/43 pts of 40BID group (due to lack of efficacy) resulted in achieving MMR for 2/8 pts with no MMR before escalation. Dose reduction in two groups was done both for adverse events (AEs) grade 3-4 (n=8) and stable MR4,5. In 4 pts (200BID) with no AEs and having a stable MR4,5 for >1 year, no MR4,5 loss was observed after ASC dose reduction to 100 mg BID. Subclone with emerging a new mutation was detected in 3 pts of 40BID group (A337T, G250A, T315I) while no new mutations were found in 200 mg BID group. AEs associated with ASC have been identified in 27/43 pts and 13/25 pts in 40BID and 200BID group, respectively, with no significant difference in AE spectrum and frequency. Most common (≥5%) AEs in two groups were: thrombocytopenia (29%), neutropenia (18%), cholesterol high (13%), anemia (6%), skin rash (5%). AEs grade 3-4 were detected in 13 (30%) and 4 (16%) pts in 40BID and 200BID group, respectively, and mostly presented by hematologic/cytopenic AEs (24%). No pt discontinued ASC due to toxicity, no arterial occlusive AEs were observed. Conclusion: ASC shows effectiveness and good safety profile in pts after prior failure to TKIs and those with T315I mutation. The CIF of any response was higher in ponatinib-naive pts at any dose. Different mutational subclones evolution was observed, including emergence of myristoyl-site mutation in 1 pt. ASC half dose reduction was safe in pts with previous MR4,5 stable response.
- Open Access
- 30 August 2023
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 23, S179
POSTER: CML-449 JAK2-Unmutated Erythrocytosis in Chronic Phase Myeloid Leukemia (CP-CML) During Tyrosine Kinase Inhibitor (TKI) Treatment
- 30 August 2023
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 23, S179
Open AccessPOSTER: CML-449 JAK2-Unmutated Erythrocytosis in Chronic Phase Myeloid Leukemia (CP-CML) During Tyrosine Kinase Inhibitor (TKI) Treatment
- Open Access
- 30 August 2023
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 23, S343-S344
CML-449 JAK2-Unmutated Erythrocytosis in Chronic Phase Myeloid Leukemia (CP-CML) During Tyrosine Kinase Inhibitor (TKI) Treatment
- 30 August 2023
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 23, S343-S344
Open AccessCML-449 JAK2-Unmutated Erythrocytosis in Chronic Phase Myeloid Leukemia (CP-CML) During Tyrosine Kinase Inhibitor (TKI) Treatment
- 1 September 2020
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 20, S242
CML-366: Baseline Cytogenetic Response Level Impact on Survival of Chronic Phase Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors as Third-Line Therapy: Real-World Data in Five Russian Centers
- 1 September 2020
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 20, S242
CML-366: Baseline Cytogenetic Response Level Impact on Survival of Chronic Phase Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors as Third-Line Therapy: Real-World Data in Five Russian Centers